ClinicalTrials.gg
RecruitingNCT07847190Updated Oct 26, 2026

Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline

A Phase 2 interventional study of Paclitaxel and Bleomycin in Germ Cell Cancer Metastatic, sponsored by Blokhin's Russian Cancer Research Center. Recruiting at 1 site in Russia. Open to male participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Blokhin's Russian Cancer Research Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Oct 2024, registered Sep 2026).
  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 26, 2026Title changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
16 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies testing paclitaxel in Testicular Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Paclitaxel · Testicular Neoplasms.

Planned enrollment
3rd of 15
60 · median 26
Started
2024
the only one that year
Phase 2
9 of 15
1 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Blokhin's Russian Cancer Research Center

Among the 15 studies testing paclitaxel in Testicular Neoplasms, this one is the 3rd largest by planned enrollment, is the only one that started in 2024, is one of 9 in phase 2, and was the 15th registered.

Testicular Neoplasms

295 studies on the registry are indexed under Testicular Neoplasms; 51 are open to participants now.

Browse Testicular Neoplasms studies →

Open to participants now

1 of the 15 studies testing paclitaxel in Testicular Neoplasms is open now, in 1 country.

By country, each count listing its studies:

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Testicular Neoplasms studies recruiting now, 26 (60%) set no upper age limit and 11 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 16 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing paclitaxel in Testicular Neoplasms, or all of them as a file.
02

Study summary

GETUG-13 study has prospectively confirmed poor outcomes in advanced germ cell tumors (GCT) patients with unfavorable decrease of tumor markers after 1 cycle of BEP chemotherapy. There is an unmet medical need to improve outcomes in this subset of patients, however the dose-dense regimen proposed in the above-mentioned trial cannot be implemented in routine clinical practice. T-BEP regimen may have advantage over the traditional BEP regimen as first-line therapy for poor-risk GCT Treatment escalation with T-BEP regimen may be an effective and tolerable therapeutic option for advanced GCT patients with unfavorable tumor markers decline.

Read the detailed description

Screening procedures:

  • AFP, b-HCG, LDH - ≤7 days before enrollment;
  • Complete blood counts;
  • Blood chemistry;
  • Urinalysis;
  • Chest, abdominal and pelvic CT-scan with IV enhancement;
  • Electrocardiogram;
  • Brain MRI scan as clinically indicated (neurologic symptoms, post-orchiectomy serum beta-hCG > 5000 IU/L or extensive lung metastasis)

Treatment:

After registration patients will receive first cycle of standard BEP chemotherapy: cisplatin 20 mg/m² IV days 1-5, etoposide 100 mg/m² IV days 1-5, bleomycin 30 mg IV days 1, 8 and 15 OR days 1, 3 and 5 + G-CSF 5 mcg/kg subcutaneous day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9. In patients with ultra-high level of tumor markers and/or poor performance status (eg, ECOG3-4) administration of a disease stabilizing chemotherapy first cycle of chemotherapy is allowed.

After 1st cycle of BEP tumor markers will be reassessed between days 18 and 21, and their kinetics will be centrally calculated (App: Tumor marker decline calculator poor-risk GCT - http://www.gustaveroussy.fr/calculation-tumor/NSGCT.html).

Patients with favorable tumor markers for both AFP and B-HCG decline will receive three subsequent cycles of BEP.

Patients with unfavorable tumor markers decline will be centrally randomized stratified by center, mediastinum primary tumor, 1st cycle in stabilizing schedule, and brain metastasis to the following arms.

  • three additional cycles of T-BEP: paclitaxel 175 mg/m2 IV days 1, cisplatin 20 mg/m² IV days 1-5, etoposide 100 mg/m² IV days 1-5, bleomycin 30 mg IV days 1, 8 and 15 OR days 1, 3 and 5 + G-CSF 5 mcg/kg subcutaneous day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9 - cycled every 21 days (experimental arm).
  • Three additional cycles of BEP: cisplatin 20 mg/m² IV days 1-5, etoposide 100 mg/m² IV days 1-5, bleomycin 30 mg IV days 1, 8 and 15 OR days 1, 3 and 5 + G-CSF 5 mcg/kg subcutaneous day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9 (standard arm).

Patients with complete response radiological and marker response after completion of chemotherapy to be followed without additional therapy (surveillance according to guidelines). Patients with radiographically detectable residual masses (eg, retroperitoneal lymph nodes, mediastinal lymph nodes, lung metastases) ≥10 mm and normal STMs (partial remission with negative STMs) should undergo surgery with goal to remove all the residual disease. If the patient considered to have unresectable tumor or to be medically inoperable the treatment approach is to be selected individually.

Patients with viable GCTs in completely resected masses (except for mature teratoma) will be managed with 2 more cycles of EP or TIP chemotherapy.

Patients are following for at least 3 years according to the following schedule: once every 2 months for 2 years, once every 4 months in the third year, once every 6 months in the fourth year, and once every year after the fourth year. Surveillance includes a clinical examination, AFP, b-HCG, LDH, creatinine, blood count, and a CT scan of the initially involved sites every 4 months for 2 years, and then once yearly in the next 3 years.

03

Conditions studied

  • Germ Cell Cancer Metastatic

Keywords

  • testis cancer
  • germ cell tumor
  • poor-prognosis non-seminomatous germ cell tumors
  • unfavorable tumor marker decline
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥16 years;
  • Evidence of NSGCT based on histologic examination or clinical evidence (high serum HCG or AFP levels - in case of clinical emergency due to bulky disease, therapy can be started without pathological confirmation of the disease);
  • Testicular, retroperitoneal, or mediastinal primary site;
  • Disease classified as poor prognosis according to IGCCCG criteria:

    • Primary mediastinal NSGCT or
    • Non-pulmonary visceral or
    • HCG > 50,000 UI/l, or AFP > 10,000 ng/ml, or LDH > 10 times the upper normal value.
  • No prior chemotherapy;
  • No concurrent which may have an impact of anticipated lifespan (ie, malignancies other than basal-cell skin carcinoma, in situ carcinomas, borderline ovarian tumors etc);
  • Adequate renal function: measured or calculated > 60 ml/min.
  • Absolute baseline granulocyte count ≥0.5*10\^9, ≥100*10\^9, ≤1.5 .
  • Unfavorable tumor marker decline after 1st cycle of standard BEP chemotherapy calculated according to time to normalization from the K. Fizazi study in JCO 2004.
  • Signed before protocol-specific procedures.

Exclusion criteria

Exclusion Criteria:

  • Primary intracranial germ-cell tumors;
  • Patients with seminomas or dysgerminomas;
  • Patients with normal range of serum tumor markers before starting treatment;
  • Patients with favorable tumor markers decline;
  • Patients infected by the (HIV);
  • Patients with to taxane agents ( to paclitaxel);
  • Patients who do not fit inclusion criteria.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    T-BEP

    Participants receive 3 cycles of T-BEP after the first cycle of the BEP regimen and unfavorable tumor marker decline, followed by standard of care surgery. Each cycle is 21 days.

    Drug: Paclitaxel · Drug: Bleomycin · Drug: Etoposide · Drug: Cisplatin · Drug: G-CSF (Filgrastim)

  • Active comparator
    BEP

    Participants receive 3 cycles of BEP after the first cycle of the BEP regimen and unfavorable tumor marker decline, followed by standard of care surgery. Each cycle is 21 days.

    Drug: Bleomycin · Drug: Etoposide · Drug: Cisplatin · Drug: G-CSF (Filgrastim)

Interventions

  • Paclitaxel 175 mg/m\^2 IV infusion, Day 1, Q3W for 3 cycles in first line

  • Bleomycin sulfate 30 mg IV infusion, Days 1,3,5, Q3W for 4 cycles in first line

  • Etoposide 100 mg/m\^2 IV infusion, Days 1-5, Q3W for 4 cycles in first line

    Also known as: VP-16

  • Cisplatin 20 mg/m\^2 IV infusion, Days 1-5, Q3W for 4 cycles in first line

  • DrugFilgrastimStudies of FilgrastimFilgrastim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    G-CSF 5 mcg/kg subcutaneous, on Day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9, Q3W for 4 cycles in first line

    Also known as: Zarzio, Tevagrastim, Neupomax

06

What researchers measure

Primary outcomes

  1. 1-year progression-free survival (PFS)

    1-year PFS is defined as time from enrollment to disease progression or relapse or death due to any cause at 1 year (12-month PFS)

    Time frame: Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~60 months)

Secondary outcomes

  1. Overall Survival

    OS is defined as time from enrollment to death due to any cause

    Time frame: Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~60 months)

  2. Complete response rate (CRS)

    CRS is defined as normalization of tumor markers and no clinical or radiological evidence of disease

    Time frame: Time from enrollment to completion of the 4th cycle of chemotherapy, disease progression, or death, whichever occurs first (up to ~48 months)

  3. Pathological complete response (pCR)

    pCR is defined as normal tumor markers and completely resected residual masses containing only necrosis or teratoma

    Time frame: Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~60 months)

  4. Adverse events

    Safety per CTCAE v5.0.

    Time frame: Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~60 months)

07

Study locations

1 of 1 sites recruiting
  • N.N. Blokhin National Medical Research Center of Oncology
    Moscow, 115522, Russia
    Recruiting
    • Edgar Israelyan, PhD · Contacte.israelyan@yandex.ru · +7-499-324-10-87
    • Alexey Rumyantsev, MD · Contacta.rumyantsev@ronc.ru · +7-499-324-10-87
    • Edgar Israelyan, PhD · Principal investigator
    • Alexey Rumyantsev, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2028, 48 months after the start.

Of 17 phase 2 interventional studies under Testicular Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 83. This study's planned 48 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartActual
Oct 1, 2024
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline: Randomized Phase II Trial
Oct 26, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Oct 26, 2026
    Title Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline: Randomized Phase II Trial
    + 1 other change: verification date
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847190
Lead sponsor
Blokhin's Russian Cancer Research Center
Collaborators
N.N. Petrov National Medical Research Center of Oncology, National Medical Research Radiological Centre of the Ministry of Health of Russia, Moscow Multidisciplinary Clinical Center "Kommunarka"
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 1, 2024
Primary completion
Oct 2028 (estimated)
Completion
Oct 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Edgar Israelyan, PhD
Contact
e.israelyan@yandex.ru
+7-919-879-92-54

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion